Outcome of imatinib discontinuation for conception
| . | Time on IM prior to discontinuation, mo . | Response at time of discontinuation . | Time off IM, mo . | Outcome on imatinib retreatment . | |
|---|---|---|---|---|---|
| N = 1071 | |||||
| 1-52 (8) | Not in CHR, n = 1 | 1-21 (7) | Minor CyR, n = 2 | ||
| (CP, n = 9; | Minor CyR = 2 | PCyR, n =3 | CHR, n = 9 | ||
| AP, n = 1) | No CyR, n = 3 | CCyR, n = 3 | |||
| PCyR, n = 3 | UNK, n = 1 | ||||
| CCyR, n = 1 | Transformation to BP, n = 1 | ||||
| N = 786 | |||||
| Sokal score | 1-50 (14) | PCyR, n = 1 | 6-23 (9) | Previous response maintained, n = 3 | |
| High, n = 1 | CCyR, n = 3 | (MMR, n = 2;CCyR, n = 1) | |||
| Low, n = 6 | MMR, n = 3 | Improvement, n = 1 | |||
| (CMR, n = 1) | |||||
| Loss of response, n = 3 | |||||
| (change to 2G-TKI, n = 2*) | |||||
| . | Time on IM prior to discontinuation, mo . | Response at time of discontinuation . | Time off IM, mo . | Outcome on imatinib retreatment . | |
|---|---|---|---|---|---|
| N = 1071 | |||||
| 1-52 (8) | Not in CHR, n = 1 | 1-21 (7) | Minor CyR, n = 2 | ||
| (CP, n = 9; | Minor CyR = 2 | PCyR, n =3 | CHR, n = 9 | ||
| AP, n = 1) | No CyR, n = 3 | CCyR, n = 3 | |||
| PCyR, n = 3 | UNK, n = 1 | ||||
| CCyR, n = 1 | Transformation to BP, n = 1 | ||||
| N = 786 | |||||
| Sokal score | 1-50 (14) | PCyR, n = 1 | 6-23 (9) | Previous response maintained, n = 3 | |
| High, n = 1 | CCyR, n = 3 | (MMR, n = 2;CCyR, n = 1) | |||
| Low, n = 6 | MMR, n = 3 | Improvement, n = 1 | |||
| (CMR, n = 1) | |||||
| Loss of response, n = 3 | |||||
| (change to 2G-TKI, n = 2*) | |||||
AP, accelerated phase; BP, blast phase; CCyR, complete cytogenetic response; CHR, complete hematological response; CP, chronic phase; CyR, cytogenetic response; IM, imatinib; MMR, major molecular response; PCyR, partial cytogenetic response. Other abbreviations are explained in Table 4.
One patient lost to follow up.